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THE RAS EFFECTOR NORE1A FORMS A TUMOR SUPPRESSOR COMPLEX 
WITH BRCA1 
Nicholas C. Nelson 
October 9th, 2015 
 Ras proteins function as molecular signaling switches that can stimulate multiple 
mitogenic pathways in response to extracellular signaling. Oncogenic activation of Ras 
by structural mutation is a highly transforming event in ~1/3 of human cancers. However, 
aberrant Ras activation can also promote oncogene-induced senescence. This Ras-
induced irreversible growth arrest is a physiological process that acts as a barrier to 
malignancy.  The mechanisms by which Ras drives senescence and how this process is 
bypassed during Ras-driven transformation remains poorly understood. 
Although mutations in the RAS gene are extremely rare in human breast cancer, 
the Ras signaling pathway is constitutively activated in roughly half of all primary breast 
tumors. This is largely due to aberrant activation of upstream regulators of Ras, like the 
EGFR family member Her2 and inactivation of negative Ras regulators, such as NF1. 
NORE1A (RASSF5) is a direct Ras effector that acts as a tumor suppressor by 
promoting apoptosis and senescence. Expression of NORE1A is frequently lost in 
primary breast tumors and breast cancer cell lines, though its mechanism of action in 
breast cancer pathogenesis remains unclear. 
vi 
BRCA1 is a tumor suppressor that plays a key role in DNA DSB repair. Loss of BRCA1 
is associated with hereditary breast and ovarian cancer, and is also thought to play a role 
in sporadic breast cancer. Recently, BRCA1 was shown to play a role in both Her2 and 
Ras senescence, but the mechanism underlying the communication between Her2/Ras 
and BRCA1 was not identified. 
I have discovered that NORE1A forms an endogenous, Her2/Ras-regulated 
complex with BRCA1. I show that dual suppression of NORE1A and BRCA1 has a 
synergistic effect on transformation. Furthermore, I show that NORE1A loss suppresses 
the BRCA1-mediated senescence effect. Finally, I show that NORE1A and BRCA1 
synergize to modulate DNA repair. Thus, I identify a novel tumor suppressor complex 
that connects Her2/Ras senescence signaling to BRCA1 in breast cancer. 
 
vii 
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Nearly two decades of research on the Harvey and Kirsten murine sarcoma 
retroviruses led to the discovery in the late 1970s and early 1980s that the sequences 
responsible for the transforming capabilities of these viral strains were actually derived 
from rat cellular genes, termed Ras (from rat sarcoma) [1]. The subsequent discovery of 
mutationally activated Ras genes in human cancer cells showed that Ras could play a role 
in human tumorigenesis [1], [2]. Intensive research into the structural, biochemical, and 
biological functions of Ras over the last thirty years has revealed much about how Ras 
communicates with both its upstream activators and downstream targets. However, the 
identification of multiple Ras regulators and effectors with unique expression patterns 
and intercellular functions has complicated the search for Ras-specific anti-cancer 
therapies [2], [3]. 
Structure and regulation of Ras 
 There are three human RAS genes (H-RAS, N-RAS, and K-RAS) that encode 
four homologous 21kDa proteins (K-RAS encodes two splice variants), all of which 
associate with cellular membranes. Ras is a guanosine nucleotide-binding protein 
(specifically, a small GTPase) that can bind and hydrolyze guanosine triphosphate (GTP) 
into guanosine diphosphate (GDP). When bound to GTP, Ras is “switched on” and can 
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bind and activate multiple signaling pathways [4]. After GTP hydrolysis, Ras undergoes a 
conformational change that “turns off” Ras signaling. Ras is normally present in this 
inactive (GDP-bound) conformation (Figure 1) [3]. 
 The process of exchanging bound GDP for GTP is facilitated by Ras GEFs 
(guanine nucleotide exchange factors). In response to external stimuli (e.g. mitogens, 
cytokines, and growth factors), Ras GEFs are recruited to Ras proteins where they 
catalyze a reaction that releases GDP from Ras [5]. Intracellular GTP is highly abundant 
compared to GDP, and preferentially enters the nucleotide binding region of Ras [6]. 
These GTP-bound Ras proteins undergo a conformational change that allows them to 
bind and activate effectors that carry information from the cell membrane to various 
intracellular signaling networks [4]. Ras has a weak intrinsic GTPase activity that can 
theoretically allow it to hydrolyze GTP and return to its inactive state in response to 
cellular feedback. This slow, inefficient process is greatly accelerated by Ras GAPs 
(GTPase activating proteins) that bind and stabilize the catalytic machinery of Ras and 
thereby enhance its hydrolytic activity [7]. It is therefore the balance between Ras GEF 
and GAP activity that regulates Ras signaling to its downstream effectors. 
In a normal cell, Ras acts as a binary signaling switch that cycles between an 
inactive (GDP-bound) state and an active (GTP-bound) state [8]. The most common 
oncogenic mutations of Ras prevent stimulation of GTP hydrolysis by Ras GAPs, 
resulting in permanently GTP-bound (i.e. constitutively active) Ras proteins that 
continuously signal to downstream pathways [9]. These activating mutations in Ras are 




 In addition to mutations in the Ras gene itself, genetic alterations in Ras 
regulatory elements can also lead to constitutive Ras signaling (Figure 2). Mutation or 
amplification of the epidermal growth factor receptor Her2, which is upstream of Ras and 
signals through Ras, accounts for ~25-30% of wild-type Ras activation in human breast 
cancer [11]–[13]. Genetic, epigenetic, or proteasomal inactivation of the Ras GAPs NF1, 
DAB2IP, and RASAL2 also account for significant wild-type Ras activation in human 
breast cancer [14]–[16]. Therefore, Ras is potentially constitutively activated in over 2/3 
of all human cancers (and nearly half of all breast cancers), making Ras and its 




Figure 1: The Ras activation/deactivation cycle is regulated by GEFs and GAPs 
Ras cycles between an active (GTP-bound) state and an inactive (GDP-bound state) due 
to regulation by its guanosine nucleotide exchange factors (GEFs) and GTPase-activating 
proteins (GAPs). GEFs release GDP from Ras, allowing Ras to preferentially bind to 
abundant intracellular GTP. Activated Ras is then able to stimulate its target effectors. 
GAPs stabilize the catalytic machinery of Ras, enhancing its intrinsic ability to hydrolyze 






Figure 2: Wild-type Ras is constitutively activated by mutations in its regulatory 
elements. 
Oncogenic Ras mutations occur in less than 2% of breast cancers, yet Ras is 
constitutively activated in over half of all primary breast tumors. This is a result of 
aberrant activation of upstream regulators of Ras that signal through Ras (such as Her2) 






Ras signaling overview 
 
Mitogenic signaling 
Activated Ras proteins promote transformation by stimulating multiple mitogenic 
pathways (Figure 3) [17]. Constitutive activation of Ras simultaneously drives cellular 
proliferation and suppresses apoptosis via these signaling pathways by enhancing 
transcription of growth factors and anti-apoptotic molecules and down-regulating pro-
apoptotic mediators [18], [19]. Two of the best-studied pathways that are activated by 
Ras are the RAF-MEK-MAPK pathway and the PI3K-AKT pathway [17]. 
In response to signaling from cell surface receptors (e.g. EGFR receptors), the 
Ras GEF Sos facilitates Ras activation, stimulating activated Ras to bind and promotes 
the phosphorylation and activation of RAF, which phosphorylates and activates MEK, 
which phosphorylates and activates ERK (MAPK). Activation of this signaling cascade 
ultimately activates the ETS family of transcription factors that induce expression of 
multiple genes that enhance cell cycle progression and migration [20]. The frequency of 
aberrant Ras-RAF pathway activation in human cancer has driven intense research into 
the development of RAF inhibitors for the treatment of these cancers [21], [22]. 
The P13K pathway is the second best characterized of the Ras effector pathways. 
Upon activation by Ras, PI3K stimulates the activation of AKT, which phosphorylates 
and activates numerous cellular proteins that lead to both the inhibition of multiple tumor 
suppressors (e.g. p53, p27, TSC1/2) and activation of multiple oncogenes [23]. 
Activation of the PI3K-AKT pathway ultimately results in cell growth and survival, cell 
cycle progression, migration, and cytoskeletal reorganization [24]. Similar to RAF, PI3K 
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mutations are frequent in human cancers, and intense research has been focused on the 
development of specific inhibitors of this pathway [23], [25].  
Ras can also bind and activate RalGDS, a guanine nucleotide exchange factor 
(GEF) for the small GTPase Ral. The interaction between Ras and RalGDS brings 
RalGDS into proximity with Ral. Activated Ral interacts with a variety of proteins, 
through which it regulates endocytosis, exocytosis, microtubule reorganization, and 
transcription [26]. Activation of these pathways ultimately enhances Ras-mediated 
transformation by promoting anchorage-independent cell growth [26]. 
 
Apoptosis 
Activated Ras is highly transforming, yet in normal cells excessive Ras activation 
can induce a powerful pro-apoptotic response (Figure 4) [27], [28]. This is usually 
mediated through p53, and acts to protect cells from transformation in the presence of 
oncogenic stimuli [28]. Signaling through the Ras effector RASSF1A can lead to 
apoptosis via activation of caspase 3 and the pro-apoptotic proteins BAX and BAK1 or 
via phosphorylation of MST kinases and activation of the pro-apoptotic Hippo pathway 
[9]. In some cases, oncogenic Ras signaling through the RAF pathway can initiate a p53-
mediated apoptotic response [29]. The paradoxical mechanism by which Ras signaling 
can both induce and abrogate apoptosis by RAF activation remains to be fully 
understood, as the outcome varies greatly depending on cell/tissue type and cellular 





In addition to activating pro-apoptotic pathways, activated Ras can also promote 
oncogene-induced senescence [28], [30]. This physiological process has been observed in 
cell culture systems and in vivo mouse models as well as human rasopathies and 
premalignant human tumors [30]–[33], and has been hypothesized to protect cells that 
acquire Ras mutations from cancer development by stimulating them to undergo 
irreversible growth arrest [34]. While the mechanism behind Ras-driven senescence 
remains poorly understood, activation of the p53-p21 and p16-Rb pathways by Ras has 
been shown to play an important role [35]. Importantly, abrogation of p53-p21 or p16-Rb 
signaling allows cells to bypass Ras-induced senescence [30]. The RASSF family 





Figure 3: Ras activates mitogenic pathways. 
Oncogenic Ras mutations lock Ras in its GTP-bound (active) state, resulting in 
constitutive Ras signaling. Mutation or overexpression of Ras regulatory elements can 
also lead to constitutive activation of wild-type Ras. The Raf pathway ultimately 
activates the ETS family of transcription factors, which stimulate the transcription of 
genes that promote cell cycle progression. Activation of PI3K-AKT leads to the 
phosphorylation and inhibition of several tumor suppressors (p27, p53, TSC1/2, BAD) or 
activation of oncogenes. Ras can also activate the small GTPases RalA and RalB via 
RalGDS, which promote anchorage-independent growth. PLCε catalyzes the formation of 
IP3 and DAG, second messengers involved in intracellular calcium release and activation 
of protein kinase C (PKC). RIN1 facilitates Ras-regulated endocytosis by acting as a GEF 
for proteins involved in endosome maturation.  






Figure 4: Activated Ras also stimulates growth inhibitory pathways. 
In addition to mitogenic signaling, activated Ras can also drive apoptosis and senescence. 
Ras signaling through Raf can promote p53-mediated apoptosis, and has also been 
implicated in senescence induction via p21 and p16. Ras-mediated activation of 
RASSF1A leads to apoptosis via activation of pro-apoptotic BAX proteins, or by 
activation of the pro-apoptotic Hippo pathway via phosphorylation of the MST kinases. 
RASSF1A has also been reported to drive senescence via p53-independent regulation of 
p21. Ras-mediated activation of NORE1A can promote p53-dependent upregulation of 





Ras growth inhibitory effectors 
 
The RASSF family 
 There are ten RASSF family members (along with various isoforms), which are 
now split into two groups: the “classical” members (RASSF1-6), which contain an RA 
domain and a SARAH domain at their C-terminus, and the N-terminal members 
(RASSF7-10) that lack a SARAH domain and contain an RA domain at their N-terminus 
[37]. Most of these proteins act as tumor suppressors in the cell and have been implicated 
in a variety of cellular mechanisms, including apoptosis, senescence, cell cycle 
regulation, and microtubule stabilization [38]. The best studied of the RASSF proteins are 
RASSF1A and NORE1A [39]. 
 NORE1A (RASSF5) can regulate Ras signaling to p53 [36], [40], and thus 
directly links Ras to this senescence pathway [41]. Epigenetic inactivation of NORE1A 
and other RASSF family members is a frequent occurrence in primary human tumors, as 





CHAPTER II: RAS SIGNALING IN BREAST CANCER 
 
Breast cancer overview 
  Breast cancer is the most common invasive cancer in women worldwide [42], and 
can be classified as either hereditary or sporadic. Inherited mutations in certain high 
penetrance genes (such as BRCA1, BRCA2, or p53) promote breast cancer formation if 
the second allele of these genes becomes inactivated [43]. The majority of breast cancers 
are sporadic, and arise from the stepwise accumulation of acquired mutations [44]. The 
mutational activation of oncogenes (like Her2) and inactivation of tumor suppressors 
leads to genomic instability via this pathway, facilitating the accumulation of additional 
mutations that can promote tumor formation. Thus, both hereditary and sporadic breast 
cancers are genetic diseases, and are associated with the loss or mutation of multiple 
regulatory genes that control proliferation, apoptosis, and differentiation [44]. 
 
Ras activation in breast cancer 
 
  The high incidence of activating Ras mutations in various cancers (e.g. 90% of 
pancreatic cancers, 50% of colon cancers, 30% of lung cancers) supports the idea that 
aberrant Ras activation is a driving force in the development and advancement of these 
malignancies [10]. The use of in vitro knockdown studies [45] and transgenic mouse 
models [46], [47] further confirmed this idea that mutant Ras is highly transforming.
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However, less than 2% of all primary breast tumors contain activating Ras mutations 
[48]–[50]. This observation has led to the widely held belief that Ras is unimportant for 
breast cancer. Yet despite the low frequency of mutations, considerable experimental 
evidence exists to support an important role for aberrant Ras activation and signaling in 
human breast tumorigenesis [11], [51], [52]. Rather than direct mutational activation, Ras 
appears to be oncogenically activated in breast cancer by mutation or altered expression 
of its upstream activators (transmembrane growth factor receptors such as EGFRs) or 
negative regulators (GAPs) (Figure 2). 
 
Ras GAPs 
  As mentioned in Chapter I, Ras cycles between an activated state (regulated by 
GEFs) and an inactivated state (regulated by GAPs). Ras GAPs are negative regulators of 
Ras that enhance its intrinsic GTPase activity. Loss or mutation of these GAPs renders 
Ras unable to return to its inactive state, resulting in constitutive Ras signaling. Several 
loss of function mutations have been discovered in the Ras GAP RASAL2, and RASAL2 
is suppressed or lost in ~20% of primary breast tumors and ~33% of breast cancer cell 
lines [14]. Additionally, the Ras GAP DAB2IP was found to be reduced by promoter 
hypermethylation in ~49% of primary breast tumors and ~48% of breast cancer cell lines 
[15]. Spontaneous loss of the Ras GAP NF1 has been shown to occur in ~28% of all 
human breast cancers [16], and is also associated with an autosomal dominant disorder 





  Human epidermal growth factor receptor 2 (Her2/Neu) is a member of the 
epidermal growth factor receptor (EGFR) family that lies upstream of Ras and signals 
through Ras [54]. In normal cells, Her2 becomes activated by ligand binding and 
transiently activates Ras, causing Ras to activate multiple downstream effectors that 
promote proliferation and survival [52]. Her2 mutation or amplification occurs in ~25-
30% of all breast cancers [11][12][13], resulting in hyper-activation of Her2 and thus 
constitutive activation of wild-type Ras. This sustained Her2/Ras activation has been 
linked to the development and progression of invasive breast carcinomas [51]. 
  Her2 activation is an early event in human breast tumorigenesis, and Her2-
positive cancers usually have a worse prognosis and an increased propensity for brain 
metastasis compared to non-Her2 cancers [55][56][57]. Paradoxically, activation of Her2 
can also promote oncogene-induced senescence [58], [59]. The molecular mechanisms 
underlying Her2-induced senescence and how it is bypassed during transformation are 
complex and remain poorly understood. One factor that clearly plays a key role is 
activation of the Ras pathway [60]. 
 
Her2/Ras activation promotes incomplete senescence in immortalized cells 
 
  Both Her2 and Ras overexpression have been reported to drive senescence in 
primary human mammary epithelial cells (HMECs) [58][61]. However, although 
oncogenic Her2 or Ras expression in MCF-10A immortalized, non-transformed human 
mammary epithelial cells results in the phenotype of senescence (senescence-associated 
morphological changes, enhanced β-galactosidase activity, upregulation of p21) it fails to 
trigger irreversible growth arrest [62]. These cells are able to stably persist in state of 
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incomplete senescence, and can be driven toward full senescence (growth arrest) or 
transformation by enhanced genotoxic stress or loss of critical cell cycle regulators [62]. 
 
NORE1A and BRCA1 link activated Ras signaling to breast cancer 
  Two tumor suppressor proteins that have been shown to play roles in both cell 
cycle regulation via p53-p21 [40], [63] and senescence via activated Ras [36], [64] are 
the RASSF family member NORE1A and the breast cancer susceptibility protein 
BRCA1. NORE1A is a direct Ras effector, and is inactivated in ~40% of breast cancer 
cell lines and primary tumors by promoter hypermethylation [65]. BRCA1 expression is 
frequently lost in sporadic breast cancers by promoter hypermethylation [66]–[69], and 
mutational inactivation of BRCA1 is linked to a hereditary breast and ovarian cancer 
(HBOC) syndrome [43]. The frequency of co-inactivation of these tumor suppressors in 
breast cancer is not known. The similar roles of these proteins in activation of the CDK 
inhibitor p21, a marker of senescence induction, coupled with their recently identified 
roles in Ras senescence suggests that these proteins may be acting to protect cells from 









 Nore1/RASSF5 was the first member of the RASSF family to be characterized 
[70]. There are three known isoforms of NORE1 as a result of alternative splicing, 
RASSF5A (NORE1A), RASSF5B, and RASSF5C (NORE1B) [38]. NORE1A is the full-
length (418aa; 47kDa) protein, and the most widely expressed. It consists of an N-
terminal proline-rich region that contains a nuclear localization sequence, followed by a 
cysteine-rich domain (CRD) that serves as a putative diacylglycerol/phorbol ester 
(DAG/PE)-binding site, a Ras association (RA) domain for binding Ras, and a C-terminal 
SARAH domain where it binds the pro-apoptotic MST kinases (Figure 5). The 
intermediate domain (INT) between the CRD and RA domains contains a second nuclear 
localization sequence, and the RA domain contains a nuclear export sequence [71]. 
 
Subcellular localization 
NORE1A is a nucleocytoplasmic shuttling protein, and contains two identified 
nuclear localization signals and one identified nuclear export signal (Figure 5). NORE1A 
has been reported on microtubules and in the centrosome [72], but can most readily be 
detected in the nucleus. Phosphorylation of NORE1A by the tyrosine kinase Lck
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regulates its nuclear translocation via an importin-mediated pathway [73]. This nuclear 
translocation of NORE1A is critical for its role in cell cycle regulation [73]. Nuclear 
export of NORE1A was shown to be required for NORE1A-mediated apoptosis induction 
[74], and likely occurs via a CRM1-mediated pathway [73], [74]. Thus, the subcellular 
localization of NORE1A plays an important role in its tumor suppressor function. 
 
Regulation and inactivation in human cancer 
NORE1A is reported to be regulated by phosphorylation by Lck [73] and Aurora 
kinase [75], and can also be poly-ubiquitinated by the E3 ubiquitin ligase Itch in a 
manner dependent on the level of NORE1A acetylation [76]. This ubiquitination results 
in NORE1A degradation by the 26S proteasome; thus, Itch acts a negative regulator of 
NORE1A [76]. The precise mechanism by which NORE1A is acetylated and marked for 
degradation remains unknown [76]. 
Another way in which NORE1A expression is regulated is by hypermethylation 
of its promoter region [77]. NORE1A is expressed in a wide variety of normal tissues, 
and is frequently downregulated by promoter hypermethylation in several cancer cell 
lines and primary tumors, including liver, lung, breast, and kidney cancers [65], [78]. 
  
Hippo signaling/apoptosis 
NORE1A lacks enzymatic activity, and therefore likely functions as a scaffolding 
protein. The best-studied functions of NORE1A are its ability to bind specifically and 
with high specificity to Ras and the proapoptotic kinase MST1, a component of the 
Hippo pathway (Figure 6). The Hippo pathway controls organ size in mammals by 
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regulating the balance between cell proliferation and apoptosis [79]. Earlier studies 
implicated Ras/NORE1A in the regulation of apoptosis via MST1 [80]. However, more 
recent research shows that while NORE1A and MST1 can form an endogenous complex 
in human cells, the kinase activity of MST1 is strongly suppressed in these complexes 
[81]. Additionally, deletion studies show that the ability of NORE1A to bind MST is not 
critical for its growth suppressive function [81]. Thus, canonical Hippo signaling via 
MST1 does not appear to be a major tumor suppressor function of NORE1A.  
 
Cell cycle regulation and senescence 
Although earlier studies identified a pro-apoptotic role for NORE1A [80], [82], 
recent research suggests that a more physiological role for NORE1A may be in the 
regulation of cell cycle arrest by p53 [40]. In support of this, NORE1A was shown to be a 
critical component of Ras-driven senescence signaling to p53 [36] (Figure 6). Senescence 
induced by Ras acts as a barrier to transformation in cells that have acquired constitutive 
activation of Ras [34]. In the absence of NORE1A, Ras becomes uncoupled from p53 and 
is able to drive transformation without the barrier of senescence [36]. Thus, the 
communication link between Ras, p53, and NORE1A is critical for the tumor suppressor 




Figure 5: NORE1A protein structure. 
Full-length NORE1A contains a proline-rich region at its N-terminus that contains a 
nuclear localization signal (aa 51-100), followed by a cysteine-rich domain (CRD; also 
referred to as a zinc-finger) that functions as a DAG/PE binding domain. The C-terminal 
end of NORE1A contains a Ras association (RA) domain where it binds to activated Ras, 
and a coiled-coil SARAH domain required for binding the MST kinases. I refer to the 
~100aa region between the CRD and RA domains as the intermediate (INT) domain. This 
INT domain is reported to contain a second nuclear localization sequence (aa 200-260). 








Figure 6: NORE1A signaling pathways 
NORE1A can bind directly to activated Ras and the proapoptotic MST kinases, which 
form the start of the Hippo signaling pathway. MST activation leads to phosphorylation 
of LATS kinases via the Salvador (SAV) adaptor protein, and ultimately the 
phosphorylation and inactivation of transcriptional co-activators YAP and TAZ. The role 
of NORE1A in Hippo signaling is controversial and remains poorly understood. 
NORE1A can also communicate with p53 to induce senescence in the presence of 
activated Ras. Recently, NORE1A was shown to scaffold the ubiquitin ligase β-TrCP 
with its target substrate β-catenin in a Ras-dependent manner, which marks β-catenin for 





NORE1A in human cancer 
 
NORE1A is frequently downregulated in human tumors and tumor cell lines by 
promoter hypermethylation [65], and loss of heterozygosity (LOH) at the NORE1A locus 
has been observed in primary tumors [84]. Furthermore, a translocation involving 
NORE1A is associated with a hereditary human cancer syndrome [85]. Overexpression 
of NORE1A can promote apoptosis [80], [82], cell cycle arrest [81], or senescence [36], 
and restoration of endogenous NORE1A levels to a human tumor cell line that is negative 
for NORE1A suppresses the tumorigenic phenotype [82]. Additionally, mouse embryonic 
fibroblasts (MEFs) from NORE1A-/- mice can be transformed by activated Ras without 
the presence of additional oncogenes, where wild-type MEFs are not susceptible to this 
one-step transformation [86]. Subcutaneous injection of activated Ras-expressing MEFs 
or NORE1A-/- MEFs into nude mice did not promote significant tumor formation after 3-
5 weeks. However, Ras+/NORE1A-/- MEFs formed tumors in these mice in 3 weeks [86]. 
Thus, the evidence supports a role for NORE1A as a tumor suppressor and Ras effector 








  The breast cancer type 1 susceptibility gene (BRCA1) is a tumor suppressor that 
functions to maintain genomic integrity, largely by participating in DNA repair. 
Hereditary mutations in BRCA1 strongly predispose carriers to developing breast and 
ovarian cancers [87]. BRCA1 inactivation by promoter hypermethylation has also been 
observed in a considerable proportion of sporadic breast cancers [88]. Thus, loss or 




 BRCA1 encodes a 1,863 AA (~220 kDa) protein (Figure 7) that plays an 
important role in maintaining genomic stability by forming protein complexes with DNA 
repair proteins and other tumor suppressors in order to carry out its diverse roles in DNA 
repair, cell cycle control, transcriptional regulation, apoptosis, and centrosome 
duplication (Figure 8) [89]. BRCA1 is able to simultaneously participate in several 
different protein complexes, as each complex contains only a small fraction of the total 
cellular BRCA1 [90].  
Three domains of BRCA1 are responsible for the majority of its biological 
functions and protein interactions: an N-terminal RING (Really Interesting New Gene) 
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domain, a central domain encoded by exons 11-13, and two tandem BRCT (BRCA1 C-
terminal) domains (Figure 7) [91]. Several cancer-associated mutations occur in these 
domains that render BRCA1 unable to interact with its target effectors [91]. 
 The sole defined enzymatic activity associated with BRCA1 occurs within its 
RING domain, which functions as an E3 ubiquitin ligase [92]. Ubiquitination of target 
substrates by BRCA1 requires interaction with an E2 ubiquitin-conjugating enzyme, and 
is significantly enhanced by formation of a heterodimer between BRCA1 and the 
BRCA1-associated RING domain protein (BARD1) [91]. Several targets of 
BRCA1/BARD1-mediated ubiquitination have been identified, including CtIP, Claspin, 
and Estrogen receptor alpha (ER-α) [93]–[95]. How these putative substrates are 
recruited to the BRCA1/BARD1 E3 ligase complex and the biological relevance of their 
ubiquitination in breast cancer remains unclear [90]. Recent in vivo studies have shown 
that the ubiquitin ligase function of BRCA1 is dispensable for tumor suppression [96]. 
Thus, the biological consequences of BRCA1-mediated ubiquitination remain to be fully 
understood. 
 The central region of BRCA1 encoded by exons 11-13 of the BRCA1 gene is 
critical for the tumor suppressor function of BRCA1 [89]. It is within this domain that 
BRCA1 becomes phosphorylated by ATM/ATR kinases in response to DNA damage, 
which enables several proteins involved in DNA repair (Rad51, BRCA2), cell cycle 
regulation (Rb) and transcriptional control (cMyc) to bind to this site [91], [97]–[100]. 
Additionally, the nuclear localization sequences of BRCA1 are contained within this 
region [101]. Mutations within this central region of BRCA1 frequently involve loss of 
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large portions of sequence, resulting in formation of a truncated protein that is unable to 
form DNA repair complexes or bind transcriptional regulators [89].  
 The BRCT domains of BRCA1 mediate DNA binding capability and 
phosphoprotein interactions involved in DNA damage repair (e.g. CtIP, Abraxas, 
BACH1, p53) [102]. Several cancer-associated mutations occur in this domain, most 
notably those that interfere with the binding of BRCA1 to p53, which is important for 
p53-dependent transcription of p21 [63]. Additionally, it is within this domain that 
BRCA1 interacts with the BRCA1-associated C-terminal helicase BACH1 [102]. 
BACH1 acts as a critical mediator of the BRCA1 DNA damage response by localizing 
BRCA1 to sites of DNA damage and using its helicase activity to provide chromatin 
access to BRCA1 and other members of the HR-mediated DNA repair complex [103]. 
Mutation or loss of BACH1 has been shown to disrupt BRCA1-mediated localization and 




Figure 7: BRCA1 protein structure. 
BRCA1 contains an N-terminal RING domain that contains its nuclear export sequence 
(NES) as well as the binding site for the BRCA1-associated Ring domain containing 
protein BARD1, which shuttles BRCA1 to the nucleus and enhances its ubiquitin ligase 
activity. The central region of the protein is encoded by exons 11-13 and contains the two 
nuclear localization sequences (NLS) and target phosphorylation sites for ATM/ATR 
kinases (SCD). Binding sites for the DNA repair proteins Rad50/51, BRCA2, PALB2, 
the tumor suppressor Rb and the oncoprotein Myc are found within this central domain. 
The two tandem C-terminal BRCT domains of BRCA1 contain binding sites for several 
phosphoproteins, including the CtBP interacting protein (CtIP), Abraxas, BACH1/BRIP1 







Figure 8: BRCA1-regulated pathways. 
BRCA1 maintains genome integrity by forming a series of complexes that regulate DNA 
repair, cell cycle progression, transcription, and ubiquitination. BRCA1 becomes 
activated by ATM/ATR kinases in response to DNA damage and is able to interact with 
its downstream targets. Some downstream targets of BRCA1 include: p53, Rb, CHK1, 
and PLK1 (involved in cell cycle regulation; apoptosis), FANCD2 (cell cycle arrest; 
homologous recombination), BARD1 (ubiquitination), XIST (X-chromosome silencing; 
non-homologous end joining), and BACH1 (chromatin remodeling, homologous 
recombination). 





BRCA1 in breast cancer 
 
  The role of BRCA1 in hereditary human cancer has been well studied [106]. Loss 
of heterozygosity in carriers of a germline BRCA1 mutation results in complete loss of 
BRCA1 function, leading to genomic instability [107]. Accumulation of DNA damage in 
the absence of BRCA1-mediated DNA repair can either activate p53-dependent pathways 
(leading to cell cycle checkpoint, growth arrest, and apoptosis or senescence) or facilitate 
further mutations that inactivate tumor suppressors or activate oncogenes (leading to 
carcinogenesis) [107]. 
  The majority (~90%) of breast cancers are sporadic, and BRCA1 mutations are 
rare in these cancers [87]. However, BRCA1 expression is suppressed in ~50% of 
sporadic breast tumors, especially those that are highly malignant [67]–[69]. Allelic loss 
and promoter hypermethylation of BRCA1 have both been demonstrated in sporadic 
breast cancers and thus may account for the observed decrease in BRCA1 expression 
[66], [108].  
 
BRCA1 regulation by Ras 
 
 Recently, a role for BRCA1 was identified in Ras-induced senescence [64]. 
Activated Ras was shown to downregulate expression of BRCA1-binding partner 
BACH1 helicase, leading to the dissociation of BRCA1 from chromatin [64]. Ras-
induced hyperproliferation in the absence of BRCA1 DNA repair leads to genomic 
instability, triggering a DNA damage response that promotes cellular senescence [109]. 
The genomic instability caused by Ras activation and subsequent BRCA1 inactivation 
can also facilitate the acquisition of secondary oncogenic hits that allow certain cells to 
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bypass senescence and become transformed [110]. Thus, BRCA1 dysregulation 
contributes to Ras-induced senescence yet renders cells susceptible to senescence bypass 
and transformation. Currently, no direct means of communication between BRCA1 and 
Ras has been established. 
 
BRCA1 and Her2 
 
 Her2 overexpression contributes to ~25-30% of Ras activation in human breast 
cancer [12]. Similar to Ras, activated Her2 expression has been shown to suppress the 
BRCA1-mediated DNA repair pathway and drive senescence [111]. These oncogene-
induced senescence pathways do not necessarily ensure complete growth arrest [62], and 
can be subverted in favor of malignancy by accumulation of additional oncogenic hits 
[64][110]. 
Her2 overexpression is not common in hereditary BRCA1 tumors, and the 
majority of findings suggest either no association or an inverse correlation between Her2 
overexpression and BRCA1 mutation in primary breast tumors [112]–[114]. However, 
two reports have shown that BRCA1 loss in Her2-positive sporadic breast tumors is 
associated with worse prognostic features (e.g. higher histological grade, increased 
proliferation) and a poor survival rate [115], [116]. Moreover, one of these studies found 
that 90% of the Her2-positive tumors in their experiments were in fact negative for 
BRCA1 [116]. While further studies are clearly required to determine the frequency and 
pathobiological characteristics of Her2+/BRCA1- tumors in sporadic breast cancer, the 
existing data supports a plausible role for BRCA1 loss in the development of Her2-





 Despite the paucity of Ras mutations, constitutive Ras activation is a frequent 
occurrence in human breast cancer, largely as a result of overexpression of its upstream 
activators (e.g. Her2) or inactivation of its negative regulators (e.g. Ras GAPs). Activated 
Ras proteins are powerfully transforming, but can also promote apoptosis and 
senescence. The paradoxical mechanism by which Ras can have both growth-promoting 
and growth-inhibitory functions remains poorly understood, but is known to involve 
activation of the tumor suppressors p53 and Rb [30] and requires expression of the 
RASSF family member NORE1A. 
NORE1A is a pro-apoptotic and pro-senescent effector of the Ras oncoprotein. 
NORE1A localizes primarily to the nucleus where it acts as a scaffold for various Ras-
regulated interactions. The growth inhibitory properties of NORE1A and its frequent loss 
in human cancers suggest that NORE1A is a tumor suppressor, though its mechanism of 
action in tumor suppression is poorly defined. 
 BRCA1 is a tumor suppressor that plays a key role in DNA repair. Loss of 
BRCA1 is associated with hereditary breast and ovarian cancer, and is also thought to 
play a role in sporadic breast tumorigenesis. 
Recently, BRCA1 was shown to play a role in Her2/Ras signaling by regulating 
senescence induction by these oncogenes [64], [111]. However, loss of BRCA1 function 
can also contribute to Ras-driven transformation [64]. The mechanism linking Ras and 
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BRCA1 is not understood. The frequent inactivation of BRCA1 in Her2-positive sporadic 
breast tumors suggests that loss of BRCA1 may also contribute to transformation in these 
cancers. 
I observed nuclear co-localization between the Ras-regulated tumor suppressors 
NORE1A and BRCA1 in human tumor cells. Both of these proteins are frequently 
inactivated in breast cancer. I designed a series of experiments to determine whether 
NORE1A and BRCA1 could form a complex, whether they could cooperate to regulate 
Her2/Ras senescence, and if their dual inactivation synergized to enhance Her2/Ras 
transformation. Furthermore, I examined the role of NORE1A on a key tumor suppressor 




MATERIALS AND METHODS 
 
Plasmids and DNA. 
 
NORE1A: Human NORE1A cDNA was obtained from Origene and confirmed by 
sequencing. HA- and KATE-NORE1A expression plasmids were generated (courtesy of 
Dr. Lee Schmidt) by cloning the full-length NORE1A cDNA as a BglII–EcoRI fragment 
into a pcDNA vector with an HA epitope tag, pmKATE2 (Evrogen) and pEGFP-C1 
(Takara Bio). NORE1A-INT domain was generated (courtesy of Dr. Lee Schmidt) by 
cloning AA 170-272 of the full-length NORE1A cDNA as a BglII-EcoRI fragment into a 
pCDNA vector with an HA epitope tag. All fusion proteins were under the control of a 
CMV promoter. shRNAs for human NORE1A (described in [36]) were obtained from 
Open Biosystems, and stable transfected cell lines were obtained after selection with 
blasticidine-S-hydrochloride (5 µg/ml; Sigma-Aldrich). 
 
BRCA1: YFP-BRCA1 was a gift from Dr. Ray White (Huntsman Cancer Institute, Utah). 
shRNAs for human BRCA1 were obtained from Origene (SKU: TG314440), and stable 
transfected cell lines were obtained after selection with puromycin dihydrochloride (1 
µg/mL; Sigma-Aldrich). 
Her2: HER2 CA (V659E) was a gift from Mien-Chie Hung (Addgene [117]), and stable 
transfected cell lines were obtained after selection with G418 Sulfate (300µg/mL; 
Cellgro). 
 




Tissue culture and cell lines. 
 
Cell lines: HEK-293T and MCF-10A cells were obtained from the ATCC (Manassas, 
VA). HEK-293T cells were grown in DMEM (Corning) with 10% FBS (Valley 
Biomedical) and 1% penicillin/streptomycin (Corning). MCF-10A cells were grown in 
DMEM/F12 medium (Corning) supplemented with 5% horse serum (Gibco), 1% 
penicillin/streptomycin (Corning), 0.5mg/mL hydrocortisone (Sigma-Aldrich), 20ng/mL 
human epidermal growth factor (EGF) (Sigma-Aldrich), and 10µg/mL human insulin 
solution (Sigma-Aldrich). 
Transfections: Stable transfectants were generated by transfecting cells each with 2µg of 
plasmid DNA using jetPRIME (PolyPlus) transfection reagent. Plasmid DNA was 
combined in a microcentrifuge tube with 200µL jetPRIME buffer and 4µL of jetPRIME 
reagent, mixed thoroughly and allowed to incubate for 10 min at room temperature. 
Transient transfections were performed by transfecting cells each with 1µg of plasmid 
DNA using jetPRIME as above. Medium was changed 24 hours after transfection, and 
cells were allowed to grow for an additional 24 hours. 
Generation of stable MCF10A cell lines: Matched sets of MCF-10A NORE1A-/BRCA1- 
cells were generated using stable sequential transduction. First, MCF10A cells were 
seeded to confluency in 100mm dishes, transfected with either 2µg of shRNA against 
BRCA1 or a scrambled pRS-vector control, and then allowed to grow at 37C for 2 days. 
Fresh growth medium (10 mL + 1 µg/mL puromycin dihydrochloride) was applied every 
day for ~2 weeks until only puromycin resistant cells remained. These cells were then 
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trypsinized and plated on a new 100mm dish and allowed to recover for 2 passages. Next, 
BRCA1- and scr control cells were plated in 100mm dishes and transfected with either a 
bRS-vector scrambled control or shRNA against NORE1A, then allowed to grow for 2 
days at 37C. These cells were then selected with 10mL media + 5 µg/ml blasticidine-S-
hydrochloride (in the same manner as before) for ~2 weeks until only blasticidine-
resistant cells remained. These cells were allowed to recover for 2 passages. This resulted 
in a matched set of 4 MCF-10A cell lines: scr/scr (vector control), vec/shBRCA1 
(BRCA1-), vec/shNORE1A (NORE1A-), shBRCA1/shNORE1A (BRCA1-/NORE1A-). 
In addition, a constitutively activated mutant of Her2 (V659E) was stably transfected into 
a set of each of these 4 cell lines. Her2+ cells were selected using 300µg/mL G418 
Sulfate in 10mL growth media in the same manner as above for ~2 weeks. All cells were 
allowed to recover for 2 passages. The end result was two matched sets of MCF-10A 
NORE1A-/BRCA1- cell lines, one Her2+ and one without Her2. 
Growth curves: MCF-10A standard growth curves were performed by plating 2x104 cells 
per 60mm dish (Cellstar), and cells from each set were trypsinized (0.25% Trypsin; 
Corning) and counted manually at the same time each day for four days. 
Soft agar assays: Soft agar assays were performed by resuspending 104 MCF-10A cells in 
standard soft agar mix (0.5mL penicillin/streptomycin (Corning), 1.8mL 10X PBS, 
1.6mL serum (Gibco), 30mL DMEM/F12 medium (Corning), 16mL melted agar (Difco)) 
and plating them on a pre-hardened 0.7% agar base in 12-well plates (Cellstar). 
Anchorage-independent growth was determined by manually counting the number of 
colonies formed in agar 2 weeks after plating the cells. 
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Senescence assays: β-galactosidase assays were performed using a BioVison kit 
(BioVision). 104 MCF-10A cells were plated in 12-well plates, fixed with 0.5mL of 
fixing solution for 15 min at room temp, washed twice with 1X PBS, and stained 
overnight at 37C with 0.5mL staining solution (470µL staining reagent, 5µL staining 
supplement, 25µL of 20mg/mL X-Gal in DMF). Senescent cells were observed and 
imaged using an IX50 inverted system microscope (Olympus) with a UPlanFl 4×/0.13 
PhL or LCPlanFl 20×/0.40 Ph1 objective (Olympus).  
Anoikis assays: Anoikis assays were performed as described in [119] [120]. Tissue 
culture wells of a 12-well plate (Cellstar) were coated with 12mg/ml Poly-HEMA 
(Sigma-Aldrich) in 95% ethanol (BDH) and allowed to dry overnight. 2x105 MCF-10A 
cells/well in 1mL growth medium were added to each well and plates were incubated at 
37C for 48 hours. Apoptosis induction through loss of cell attachment was measured by 
mixing 0.5mL of cell suspension with 0.1mL of 0.4% Trypan Blue solution (Life 
Technologies), filling a hemocytometer, and manually counting the number of viable and 
non-viable cells. These results were compared to viability counts for control cells grown 
simultaneously in 12-well plates without Poly-HEMA coating. 
Replication stress: To induce replication stress, HEK-293T cells were treated with 2mM 
hydroxyurea (Sigma-Aldrich) in cell culture media for 6 hours as described in [121]. 
Comet assays: Sub-confluent MCF-10A cells were treated with doxorubicin 
hydrochloride (0.3 µg/mL; Sigma-Aldrich) for 24 hours to induce DNA damage. DNA 
damage was then assayed using a CometAssay Kit (Trevigen). Cells were harvested and 
resuspended at 1 x 105 in sterile PBS, and combined at a ratio of 1:10 with molten 
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LMAgarose. 50µL of the cell/agarose mixture was plated on a CometSlide and allowed 
to cool for 30 min at 4C. Slides were then immersed in 4C lysis solution for 1 hour, and 
then immersed in Alkaline Unwinding solution (0.4g NaOH, 250µL 200mM EDTA, 
49.75mL dH2O) for 1 hour at room temperature in a sealed plastic Coplin staining jar. 
Slides were then placed immersed in ~800mL Alkaline Electrophoresis solution (8g 
NAOH, 2mL 500mM EDTA, 1L dH2O) in an electrophoresis tray and power supply was 
set to 21 volts for ~30 minutes. Electrophoresis solution was drained from slides, and 
they were gently immersed 2 x 5 min in H2O and then 1 x 5 min in 70% EtOH. Slides 
were then dried for ~45 minutes at 37C and the dried agarose was stained with 100µL of 
SYBR green DNA stain (ThermoFisher Scientific) for 30 min at room temp in the dark. 
Slides were tapped gently to remove excess stain, rinsed briefly in dH2O and allowed to 
dry completely at 37C (~30min). Slides were then visualized on an Olympus 
fluorescence inverted microscope or an Evos FL Cell Imaging System (ThermoFisher 
Scientific) at 100x magnification.  Comet tails from 100 (randomly selected) cells were 
scored using OpenComet software for ImageJ based on their DNA content (intensity) 
[122]. DNA damage was quantified as comet tail moment, defined as the product of the 
tail length and the fraction of total DNA in the tail. 
Fluorescent microscopy: GFP and RFP proteins were visualized at room temperature in 
live cells in growth medium using an IX50 inverted microscope (Olympus) with a 
UPlanFl 100×/1.3 oil immersion objective (Olympus) and a SPOT camera (Diagnostic 





Monoclonal and polyclonal NORE1A antibodies have been described previously [36]. 
The PAS 17072 NORE1A antibody was used at 1:500 dilution in 5% powdered milk + 
TBST. Mouse monoclonal HA antibodies (used at 1:5k dilution in 5% milk + TBST) 
were obtained from Covance, and mouse monoclonal GFP and BRCA1 antibodies (1:200 
dilution in 5% milk + TBST) were from Santa Cruz Biotechnology, Inc. Mouse 
monoclonal β-actin antibodies (1:10k dilution in 5% milk + TBST) were obtained from 
Sigma-Aldrich. Rabbit polyclonal p21 and Her2 (1:1k dilution in 5% BSA + TBST) 
antibodies were obtained from Cell Signaling Technology. Mouse monoclonal c-Myc 
(1:5k dilution in 5% milk + TBST) antibodies were obtained from Thermo Scientific. 
Goat anti–mouse and anti–rabbit secondary antibodies conjugated to peroxidase (used at 
1:10k-20k dilution in TBST) were obtained from Thermo Fisher Scientific. 
 
Western analysis and immunoprecipitation. 
 
Signaling assays: MCF-10A cells were seeded at confluence and grown in a 37C 
incubator overnight. Cells were lysed in 100 µL RIPA buffer (Sigma-Aldrich) with 
sodium orthovanadate (Sigma-Aldrich) and protease inhibitor cocktail (Sigma-Aldrich 
cat # P8340) added just prior to lysis, and the concentration of protein in the lysates was 
quantified using a Bio-Rad protein assay (Bio-Rad) using a spectrophotometer (abs: 595). 
Equal amounts of protein lysate were combined 1:1 with Laemmli Sample Buffer (Bio-
Rad) and 16-20 µL total was loaded onto a 4-15% Tris-glycine gel (Bio-Rad) and run for 
~1 hr at 120 volts using a Mini-PROTEAN electrophoresis system (Bio-Rad). Gels were 
then transferred at 4C for ~4 hours at 20 volts to a 0.2µm nitrocellulose membrane (Bio-
Rad). Membranes were blocked at room temperature for 1 hr in 5% powdered milk + 
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TBST solution and incubated in the appropriate primary antibody (1:200-1:10,000) in 5% 
milk + TBST or 5% BSA + TBST solution overnight at 4C, washed 5 x 5min in TBST 
(Tris-buffered saline (Corning), 0.1% Tween 20 (Sigma-Aldrich)), incubated with the 
appropriate secondary antibody (1:10,000-1:20,000) in TBST for 1 hr, and washed again 
for 5 x 5 min in TBST. Nitrocellulose membranes were then incubated in 4 mL of Pierce 
ECL solution (2 mL of stable peroxide solution + 2 mL of luminol/enhancer solution; 
Thermo Scientific, Rockford, IL) for 2-5 minutes with constant rocking, placed inside a 
standard film cassette and developed using X-Ray film (MidSci, Valley Park, MO). 
 
Co-immunoprecipitation: Cells were lysed in 100-200 µL modified RIPA buffer (150mM 
NaCl, 50mM Tris (Cellgro), pH 7.5, 1% Tergitol NP-40 (Sigma-Aldrich)) with protease 
inhibitors added prior to lysis as above. Precleared lysates were immunoprecipitated 
overnight with GFP-Trap agarose beads (Allele Biotech, San Diego CA) or primary 
antibody as appropriate and washed 3 x 3min with lysis buffer, then Western blotted as 
above.  
 
Image acquisition and processing. 
 
All images were scanned and quantified using a Pharos FX plus Molecular Imager (Bio-
Rad) and Quantity One software (Bio-Rad) or ImageJ software. Linear range was 
determined for individual antibodies by plotting the quantitated densities of Western 
blotted bands against the initial amount of protein lysate loaded in each lane. To control 
for variability, the background-subtracted densities of each protein of interest and 
normalizing control (e.g. beta-actin) were quantified and protein of interest values were 
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divided by relative normalized control values in their respective lanes. For quantitative 
experiments, each condition was performed in duplicate or triplicate as described. For 
statistical comparison, one-way analysis of variance (ANOVA) was used to determine if 
mean differences existed across groups (ctrl, shB, shN, shBN) following each 
experimental condition. The null hypothesis used was that all means were equal. If at 
least two means were identified as significantly different (critical value method = F>Fcrit 
or p-value method = p < 0.05), post hoc Student’s t-tests were applied. Averages, p-
values, and fold-changes were calculated and the results graphed using Excel (Microsoft). 









Ras is constitutively activated in breast cancer.  
 Mutational activation of the Ras oncogene is found in ~1/3 of all human cancers, 
making Ras the most common oncogene in human cancer [123]. Ras mutations are 
infrequent in breast cancer [48]–[50]; however, persistent upstream signaling by the 
growth factor receptor Her2 results in constitutive activation of wild-type Ras in ~25-
30% of human breast cancers [11]–[13]. Mutations in Ras GAPs (e.g. NF1, RASAL2, 
and DAB2IP) lead to constitutive Ras activation in up to 50% of human breast cancers 
[14]–[16]. Thus, the Ras signaling pathway is hyperactivated in a large percentage of all 
human breast cancers. 
 
Her2 and Ras activation can drive senescence or transformation. 
 Constitutive activation of Ras drives growth and transformation by binding and 
activating multiple effectors that stimulate various mitogenic pathways, the best 
characterized of which are the Raf and PI3K pathways [17]. Accordingly, activation of 
Her2 can also promote transformation via Ras signaling pathways [11], [52], [124], 
[125]. Paradoxically, activation of Her2 and Ras can also promote cellular senescence, an 
irreversible cell growth arrest [30], [59]. This oncogene-induced senescence represents an 
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early barrier to Her2/Ras transformation, and is thus an important tumor suppressor 
mechanism in vivo [126]. In order to become cancerous, cells must acquire mutations or 
epigenetic changes that allow them to subvert the senescence program. The mechanism 
by which activated Her2/Ras drives senescence and how this is bypassed during 
transformation remains poorly understood [127]. 
 
NORE1A is a critical Ras senescence effector. 
NORE1A (RASSF5) is a member of the Ras-association domain family (RASSF) 
of tumor suppressors that binds activated Ras and mediates its growth inhibitory 
properties [36][81][86]. NORE1A is frequently downregulated in primary human tumors 
and breast cancer cell lines by promoter hypermethylation [65], and a translocation 
involving NORE1A is associated with a hereditary human cancer syndrome [85]. Thus, 
NORE1A acts as a tumor suppressor, though its mode of action in tumor suppression and 
Ras-mediated growth inhibition remains poorly understood. 
 NORE1A lacks enzymatic activity and has been shown to act as a scaffolding 
molecule [36]. Similar to other RASSF proteins, NORE1A can bind the proapoptotic 
MST kinases which begin the canonical Hippo pathway [80]. However, the interaction 
with MST is not required for NORE1A tumor suppressor activity [81], suggesting that 
other interactions are key to this function. Although NORE1A overexpression can induce 
apoptosis, when expressed at more physiological levels NORE1A induces cell cycle 
arrest by promoting the p53-mediated activation of p21 [40]. 
In the presence of activated Ras, NORE1A acts as a critical component in Ras-
mediated senescence signaling to p53 [36]. NORE1A facilitates Ras senescence by 
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scaffolding p53 in a nuclear complex with the kinase HIPK2 that mediates the pro-
senescent acetylation of p53 [36]. Loss of NORE1A (at least, partially) uncouples Ras 
from p53 and abrogates its ability to induce senescence [36], [40]. Consequently, loss of 
NORE1A expression can facilitate senescence bypass and transformation in response to 
activated Ras signaling. 
 
BRCA1 plays a role in Her2/Ras senescence 
 Oncogene-induced senescence is often characterized by the accumulation of DNA 
double strand breaks (DSBs) [109], [126]. This is largely due to replication fork stalling 
and collapse caused by aberrant DNA replication in response to hyperactive Ras 
signaling [126]. Under normal conditions, DNA DSB accumulation would lead to 
initiation of checkpoint activation, cell cycle arrest, and formation of DNA repair 
complexes at stalled replication forks mediated by the breast cancer susceptibility protein 
BRCA1 [128]. However, activation of Her2/Ras suppresses BRCA1-mediated DNA 
repair [64][111]. Oncogene-induced hyperproliferation in the absence of BRCA1 DNA 
repair mechanisms produces sufficient replication stress and accumulation of DNA DSBs 
to initiate a senescence response [64][111]. The role of BRCA1 in Her2/Ras-mediated 
senescence remains ill defined [129], as currently no direct mechanism of communication 
between Ras and BRCA1 has been identified. 
 
Summary 
Both NORE1A and BRCA1 mediate Ras senescence, modulate p21 expression, 
and are downregulated in breast cancer. The connection between Her2/Ras and BRCA1 
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is not known. I decided to examine the possibility that NORE1A might connect Ras (and 
therefore, Her2) to BRCA1. Using activated Her2 as a model of constitutive Ras 
signaling, I now show that NORE1A and BRCA1 form a physiological, Her2-regulated 
complex in human cells. In response to aberrant Her2/Ras signaling, NORE1A appears to 
localize BRCA1 to stalled replication forks. Thus, the cellular levels of NORE1A may 
dictate how Ras mediates the localization and function of BRCA1. Moreover, the 







NORE1A and BRCA1 co-localize in the nucleus. 
NORE1A functions as a scaffolding molecule, and has been shown to promote the 
nuclear localization and activation of the tumor suppressor p53 [40]. BRCA1 contains 
two nuclear localization sequences (NLS) that mediate its transport from the cytosol to 
the nucleus (Figure 7). The nuclear localization of BRCA1 is important for its tumor 
suppressor ability [130], as loss of this localization renders BRCA1 unable to participate 
in DNA repair and subsequently leads to an increase in unrepaired mutations and 
chromosomal abnormalities [91]. Accordingly, in nearly all primary breast tumors and 
breast cancer cell lines that express BRCA1, it is largely localized in the cytoplasm [131]. 
To determine if NORE1A expression could alter the subcellular localization BRCA1, I 
overexpressed RFP-tagged NORE1A and YFP-tagged BRCA1 in HEK-293T cells. 
Figure 9 shows that BRCA1 and NORE1A co-expression shifted a fraction of total 
cellular BRCA1 into nuclear foci with NORE1A, suggesting that NORE1A is recruiting 
BRCA1 to these nuclear foci. 
Although breast cancer seldom exhibits Ras mutations, mutation or 
overexpression of the upstream Ras activator Her2 occurs in 25-30% of all breast cancers 
[12]. NORE1A is a direct effector of Ras, and BRCA1 has also been shown to play a role 
in Ras signaling [64]. To determine whether Her2 (and thus Ras) signaling could regulate 
NORE1A/BRCA1 co-localization, I overexpressed a constitutively activated Her2 mutant 
(V659E) in HEK-293T cells with my fluorescently tagged NORE1A and BRCA1. Figure 
9 shows that addition of Her2 (V659E) enhanced the size of the observed nuclear foci 
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formed by NORE1A/BRCA1 co-localization, suggesting that Her2/Ras signaling 
enhances the ability of NORE1A to recruit BRCA1 to the nucleus. 
Activation of oncogenes like Her2 or Ras promotes hyperproliferation, which can 
lead to replication stress induced by deoxyribonucleotide pool depletion [132][133]. 
BRCA1 responds to this replication stress by forming protein complexes at stalled 
replication forks to protect and repair damaged DNA [134]. Since NORE1A can promote 
the nuclear localization of BRCA1 in the presence of activated Her2 signaling, I 
wondered if these proteins were co-localizing at stalled replication forks in response to 
oncogene-induced replication stress. To determine if this was the case, I treated cells co-
expressing YFP-BRCA1 and RFP-NORE1A with 2mM hydroxyurea (HU) for 6 hours, as 
described in [135]. HU depletes cells of dNTP pools, which slows/stalls replication 
machinery, generating a replication stress response [135]. Thus, HU treatment promotes 
replication stress via a similar mechanism as activated Her2/Ras. Figure 9 shows that 




Figure 9: NORE1A and BRCA1 co-localize after replication stress. 
HEK-293T cells were transfected with GFP-vector or YFP-tagged BRCA1 and RFP-
NORE1A, in the presence or absence of Her2 (V659E), and images were captured 24 
hours later using a fluorescence microscope (magnification = 1000x). A group of cells 





NORE1A and BRCA1 form an endogenous Her2 and Ras-regulated complex. 
 NORE1A is a direct Ras effector that mediates the growth inhibitory properties of 
Ras. BRCA1 functions as a tumor suppressor by forming protein complexes in the cell 
important for maintaining genome integrity [91], and can also play a role in Her2/Ras 
signaling [64][111]. Currently, no direct mechanism of communication between Ras and 
BRCA1 has been discovered. Since I observed NORE1A recruiting BRCA1 to nuclear 
foci in response to activated Her2 (and thus Ras) signaling, I wondered whether Her2 
could regulate their complex formation. This would suggest the existence of a 
Her2/Ras/BRCA1 signaling pathway. 
 To determine if NORE1A and BRCA1 could form a physiological complex in 
human mammary cells, I stably transfected MCF-10A cells with Her2 (V659E) or a 
vector control, immunoprecipitated cell lysates with NORE1A, and immunoblotted for 
BRCA1. In the absence of activated Her2 I was able to detect a modest association 
between endogenous NORE1A and BRCA1 proteins. However, when cells were stably 
transfected with activated Her2, the association of endogenous NORE1A with 
endogenous BRCA1 was greatly enhanced (Figure 10A). As further confirmation, 
exogenous expression of NORE1A and BRCA1 in HEK-293T cells challenged with 




Figure 10: NORE1A and BRCA1 form a Her2 and Ras-regulated complex. 
(A) Equal amounts of protein lysate from MCF-10A human breast epithelial cells stably 
transfected with Her2 (V659E) or a vector control were immunoprecipitated (IP) with 
anti-NORE1A antibody, fractionated on an SDS-polyacrylamide gel, and then 
immunoblotted (IB) for the presence of BRCA1 in the complex. Cell lysate 
immunoprecipitated with IgG alone and lysis buffer immunoprecipitated with NORE1A 
antibody were used as negative controls. (B) HEK-293T cells were transiently transfected 
with either YFP-tagged BRCA1 or HA-tagged NORE1A in the presence or absence of K-
Ras12V or Her2 (V659E) expression constructs. Cells were lysed 24 hours after 
transfection and equal amounts of protein were immunoprecipitated for GFP. The 
immunoprecipitate was fractionated on an SDS-polyacrylamide gel and then 
immunoblotted with anti-HA and anti-GFP antibodies. Fold change was calculated after 
normalizing to total HA-NORE1A expression levels in addition to total BRCA1 







BRCA1 binds the INT-domain of NORE1A. 
 NORE1A has several protein binding domains that have been identified, 
including a Ras-binding domain and C-terminal SARAH domain that binds the MST 
kinases (Figure 5). In addition, NORE1A contains a stretch of ~100aa that lies between 
the DAG/PE binding domain and Ras-association (RA) domain which my laboratory has 
termed the intermediate (INT) domain (Figure 11A). This domain is relatively 
uncharacterized, but does contain several putative phosphorylation sites, as predicted by 
the Netphos tool (sensitivity 69-96%) [136]. These include S177 (score = 87%), S182 
(99%), T186 (87%), T202 (98%), and S260 (99%). 
To further characterize the interaction between NORE1A and BRCA1, I co-
overexpressed serial deletions of NORE1A with full-length BRCA1 in HEK-293T cells. I 
determined that BRCA1 could interact with the INT domain of NORE1A (Figure 11B). 
Since the INT domain is a fragment of the full-length NORE1A protein that can bind 
BRCA1, I hypothesized that it could be used as a dominant-negative for the 
NORE1A/BRCA1 interaction. Specifically, that overexpression of the INT domain might 
block the binding of full-length NORE1A to BRCA1. Since NORE1A and BRCA1 act as 
tumor suppressors in the cell, I hypothesized that blocking their interaction could have a 
transforming effect on cells. 
 To determine whether overexpression of the INT-domain had an effect on the 
morphology or growth of non-transformed cells, I stably overexpressed the INT-domain 
into MCF-10A human mammary epithelial cells, which are non-transformed. I observed 
that overexpression of the INT-domain in these cells caused them to exhibit a 
transformed phenotype, as indicated by their enhanced ability to grow under anchorage-
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independent conditions in soft agar compared to control MCF-10A cells (Figure 11C). 
Thus, overexpression of a fragment of the tumor suppressor NORE1A—that I have 
shown can bind BRCA1—had a transforming effect. This is, to my knowledge, the first 
identification of a transforming capacity in a RASSF tumor suppressor. This result also 
implies that blocking the NORE1A/BRCA1 interaction could be transforming. Further 




Figure 11: BRCA1 binds the INT-domain of NORE1A. 
(A) Location of the NORE1A-INT domain within the full-length NORE1A protein and 
its ~100 AA sequence. Asterisks indicate potential S/T phosphorylation sites (score 
>97% [136]). (B) HEK-293T cells were transiently transfected with either GFP-tagged 
BRCA1 or NORE1A-INT expression constructs. Cells were lysed 24 hours after 
transfection and equal amounts of protein were immunoprecipitated (IP) for GFP. The 
immunoprecipitate was fractionated on an SDS-polyacrylamide gel and then 
immunoblotted (IB) with anti-HA and anti-GFP antibodies. (C) MCF-10A cells stably 
transfected with HA-vector or HA-tagged NORE1A-INT domain were plated in soft agar 
and grown for 2 weeks at 37C. Representative images are from 2 independent 












 Ras is the most frequently mutated oncogene in human cancer. The low 
percentage of breast cancers with Ras mutations led to the theory that Ras does not play 
an important role in breast tumorigenesis [11]. However, the Ras signaling pathway is 
constitutively activated in over half of all breast tumors due to persistent upstream 
signaling by the EGFR family member Her2 [11], [124], [125] or certain Ras GAPs [14]–
[16]. 
Her2 overexpression is an early-occurring and highly transforming event in breast 
cancer [52]. Her2+ breast cancers usually have much worse prognosis and propensity for 
metastasis than non-Her2 breast cancers [55]–[57]. The majority of Her2+ primary breast 
tumors have lost expression of the tumor suppressor BRCA1 [115], [116]. This is 
paradoxical, as Her2 or Ras-mediated inactivation of BRCA1 in non-transformed cells 
promotes senescence [64], [111]. Therefore, additional oncogenic mutations must be 
occurring that are allowing these Her2+/BRCA1- cells to bypass senescence and undergo 
transformation. 
The most important tumor suppressor function of BRCA1 is its ability to localize 
to the nucleus in response to replication stress and participate in DNA repair [137]. In 
nearly all primary breast tumors and breast cancer cell lines that retain BRCA1 
expression, it is predominantly localized to the cytoplasm [131]. I have shown that Her2 
overexpression can promote the nuclear localization of BRCA1 in human tumor cells. In 
addition, Her2 promoted the co-localization of BRCA1 with the Ras effector NORE1A. 
NORE1A has been shown to act as a nuclear localization factor for the tumor suppressor 
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p53 [40]; thus, I hypothesized that NORE1A was recruiting BRCA1 to the nucleus in 
response to aberrant Her2/Ras activation. 
NORE1A appears to be acting as a direct communication link between BRCA1 
and Ras signaling. I showed that NORE1A forms an endogenous, Her2/Ras-regulated 
complex with BRCA1 that mediates its subcellular localization. Thus, the interaction 
between these two proteins is physiological, though whether it is occurring directly or as 
part of a larger DNA repair complex remains to be determined. 
I mapped the BRCA1 binding domain down to a ~100 amino acid region of the 
full-length NORE1A protein that my laboratory termed the NORE1A-INT domain. This 
domain was previously shown to be indispensible for NORE1A-mediated growth 
inhibition [81]. However, the mechanism of action of the INT domain remains to be fully 
investigated. Using an artificial neural network that predicts phosphorylation sites [136], 
I found several putative consensus phosphorylation sites for S/T kinases within the INT 
domain, suggesting that it may serve as a potential interaction site of NORE1A with 
numerous kinases. Two of these consensus phosphorylation sites (T202 and S260) are 
particularly interesting, as NORE1A contains a nuclear localization sequence in this 
region of the INT domain (aa 200-260). Phosphorylation of NORE1A has been shown to 
regulate its subcellular localization, and subsequently its function within the cell [73]–
[75]. Thus, kinase interactions within the INT domain could regulate the subcellular 
localization of NORE1A. This could explain previous reports that the INT domain was 
indispensible for growth inhibition [81].  
My observation that overexpressing the INT domain in MCF-10A non-
transformed human breast epithelial cells caused these cell to exhibit a transformed 
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phenotype is, to my knowledge, the first identification of a transforming capacity in a 
RASSF tumor suppressor. One possibility is that the INT domain is competing with full-
length NORE1A for binding to BRCA1, and overexpressing the INT domain is 
effectively blocking the NORE1A/BRCA1 interaction. Whether blocking the 
NORE1A/BRCA1 interaction is transforming is not known; however, this could be 
determined by knocking down expression of NORE1A and BRCA1 in a non-transformed 
cell line. 
BRCA1 and NORE1A are both frequently inactivated in human tumors by 
promoter hypermethylation [65], [66]. The rate of their co-inactivation in breast cancer is 
not known. I hypothesize that co-inactivation of NORE1A and BRCA1 would result in 
decreased senescence induction by activated Her2/Ras, likely contributing to the worse 
prognosis seen in Her2+ breast tumors. The expression status of NORE1A/BRCA1 in 
these tumors may be difficult to determine by methylation analysis alone, as NORE1A 
can also be regulated at the mRNA [138] and protein levels [139]. Protein array analysis 
from breast tissue tumor samples would be necessary to determine more accurate 
NORE1A/BRCA1 expression levels. 
Thus, I identify a novel Her2-Ras-NORE1A-BRCA1 pathway that links activated 
Her2 and Ras signaling to BRCA1. This pathway has the potential to be constitutively 
activated in over half of all breast cancers due to the high frequency of aberrant Her2/Ras 
activation in these cancers. 
I propose a scenario in which NORE1A and BRCA1 form a complex to repair or 
maintain integrity of stalled replication forks in response to the increase in proliferation 
stimulated by physiological Her2/Ras activation. The role of NORE1A/BRCA1 complex 
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formation in Her2/Ras-mediated human breast tumorigenesis remains to be determined. 
Since NORE1A and BRCA1 act as barriers to Ras transformation, loss of complex 
formation between these tumor suppressors could shift the balance of Her2/Ras signaling 








Constitutive Her2/Ras activation can drive senescence or transformation. 
Constitutive activation of Ras signaling pathways occurs in over half of all breast 
cancers, for the most part due to mutation or amplification of its upstream activator Her2 
[11]–[16]. Up to 90% of Her2+ sporadic breast tumors are negative for BRCA1 
expression, and these tumors have a worse prognosis and poorer survival rate than non-
Her2+ tumors [115], [116]. The underlying paradox is that Her2/Ras activation or 
BRCA1 inactivation in normal cells promotes senescence [59], [64]. Thus, loss of 
additional senescence regulators must be occurring that are driving these cells toward 
malignancy. 
Aberrant activation of Her2/Ras induces hyperproliferation, which triggers a 
DNA damage response that drives premature senescence in cells as a precaution against 
malignant transformation [109], [140]. This oncogene-induced senescence induction is 
characterized by an upregulation of certain tumor suppressor pathways, like the p53-p21 
and p16-Rb pathways. 
Once cells have become immortalized, their response to activated Ras signaling 
changes. For example, activation of Her2 and Ras in MCF-10A human mammary 
epithelial cells (which have reactivated telomerase [141]) promotes the biomarkers of 
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senescence (e.g. enhanced SA-β-gal activity and upregulation of p21) yet fails to trigger 
irreversible growth arrest [62]. This state of incomplete senescence (referred to as the 
SWING state by Sherman et al.) is stable, and is suggested to be an intermediary step 
between activation of oncogenes and cellular senescence or transformation [62]. 
Accordingly, cells residing in the SWING state can be manipulated to senesce or 
transform via enhanced genotoxic stress or loss of p53-p21 signaling [62]. 
 
Her2/Ras senescence requires activation of p21. 
Her2/Ras-driven senescence is dependent on the upregulation of p21, and does 
not occur in p21- or p53-knockdown cells [142]. Similarly, formation of the intermediary 
SWING state in MCF-10A cells is dependent on Her2/Ras-induced upregulation of p21 
[62][111]. Thus, in order for immortalized MCF-10A cells (which lack p16) to bypass 
senescence, they must lose the ability to activate p21. 
Expression of p21 is tightly controlled by the tumor suppressor p53, through 
which p21 mediates G1 cell cycle arrest in response to various cellular stressors [143]. In 
response to oncogene activation, p53 becomes activated and transactivates p21 to drive 
senescence [144], [145]. Nuclear localization of p53 is critical for its transactivation 
function, and its sequestration in the cytoplasm has been observed in human tumors 
[146]. 
The tumor suppressor and Ras senescence effector NORE1A plays a key role in 
regulation of the cell cycle by p53-p21 signaling. In response to Ras activation, NORE1A 
binds p53 and promotes its nuclear localization, leading to the upregulation of p21 and 
induction of senescence [36], [40]. NORE1A loss in primary human tumors has been 
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shown to tightly correlate with loss of p21 expression [40]. Thus, NORE1A is critical 
regulator of Ras senescence that connects Ras to p53-p21 signaling. 
 Overexpression of the DNA repair protein BRCA1 can also regulate p53/p21 
signaling. BRCA1 interacts directly with p53 [63] and can act as a coactivator of p21 
transcription in response to DNA damage [147]. Interestingly, loss of expression of 
BRCA1 can also activate p53-p21 signaling by triggering a DNA damage response that 
promotes senescence [64]. This appears to be part of a controlled suicide response to 
oncogene activation, as both aberrant Her2 and Ras signaling can promote BRCA1 
inactivation [64], [111]. Thus, under physiological conditions BRCA1 can activate p53-
p21 signaling to temporarily stall the cell cycle, and under aberrant conditions BRCA1 
loss activates p53-p21 signaling to shut down the cell cycle. 
The “Goldilocks” response and senescence 
 Both activation of Her2/Ras and inactivation of BRCA1 can drive senescence 
[62], [64], [111], [148]. In other words, cells are programmed to commit suicide in 
response to genomic stressors like “too much” oncogene (Her2/Ras) activation or “too 
little” tumor suppressor (BRCA1) expression in order to avoid malignancy. This effect 
where senescence is initiated in response to elevated Her2/Ras or inactivated BRCA1 is 
hereafter referred to as the “Goldilocks” response. 
I provided evidence in Chapter V that suggested the existence of a 
Her2/Ras/NORE1A/BRCA1 signaling pathway. NORE1A is required for senescence 
after Ras activation [41]. Since Her2 lies upstream of Ras and signals through Ras 
pathways [11], [12], I was curious to determine if NORE1A could monitor the senescent 
response to Her2 activation via the same pathway. Since I showed that NORE1A could 
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link BRCA1 to Ras signaling, I also wondered whether NORE1A was required for 
BRCA1 to drive senescence after oncogene activation. Thus, I hypothesized that 




 In the preceding chapter I introduced a physiological, Her2/Ras regulated 
interaction between NORE1A and the breast cancer associated protein BRCA1. 
Her2/Ras-mediated inactivation of BRCA1 was shown to enhance p21 expression and 
promotes senescence [64], [111]. I hypothesized that inactivation of NORE1A would 
impair this Her2/Ras/BRCA1 senescence pathway. 
 I show here that NORE1A inactivation suppresses Her2+ senescence, and that 
dual inactivation of NORE1A and BRCA1 has a synergistic effect on Her2/Ras 
transformation. Furthermore, I show that dual inactivation of NORE1A and BRCA1 is 
sufficient to transform MCF-10A cells in the absence of additional stimuli. This is due in 
part to anoikis resistance in these cells. This data suggests that NORE1A monitors the 
“Goldilocks” response to Her2/Ras activation and BRCA1 inactivation; NORE1A 
expression must be “just right”, or cells cannot activate apoptosis or senescence in 






Generation of NORE1A/BRCA1 stable double knockdown cells. 
 I showed previously that NORE1A and BRCA1 form a Her2/Ras-regulated 
complex in MCF-10A cells. To examine the role of NORE1A and BRCA1 complex 
formation in neoplastic transformation of these cells, I generated a matched set of stable 
NORE1A/BRCA1 double knockdown clones by sequential shRNA vector transduction, 
which resulted in 80% BRCA1 depletion in BRCA1 knockdown cells, 60% NORE1A 
depletion in NORE1A knockdown cells, and 91% NORE1A and 96% BRCA1 depletion 
in the double knockdown cells (Fig. 12A). Standard growth analysis revealed that 
individual depletion of NORE1A or BRCA1 enhanced the proliferation of MCF-10A 
cells ~1.5-fold and ~2.5 fold, respectively, compared to vector control cells, and dual 
depletion of NORE1A and BRCA1 had an additive effect (Fig. 13). This suggests that 
dual inactivation of these proteins is having an effect on cell cycle regulation. 
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Figure 12: Generation of MCF-10A knockdown cell lines. 
(A) Western blot analysis of NORE1A and BRCA1 expression in MCF-10A 
immortalized human mammary epithelial cells. Expression levels of NORE1A and 
BRCA1 were quantified after sequential stable transduction of shRNA against NORE1A 
or BRCA1 or a scrambled control into these cells. The density of the bands was 
quantified using ImageJ software and relative BRCA1 or NORE1A expression was 
calculated after normalizing to β-actin expression. (B) Western blot analysis of Her2 
expression in shBRCA1/shNORE1A MCF-10A cells. Her2 (V659E) was stably 
overexpressed in the matched set of MCF-10A knockdown cells from (A) and its 






Figure 13: Depletion of NORE1A or BRCA1 enhances growth of MCF-10A cells. 
Matched sets of knockdown MCF-10A cells were plated at 2x104 and grown in 2D 
culture for 4 days. Cells were trypsinized and counted each day. (bottom) Relative 
changes in growth between each set at Day 4 expressed as a bar graph. Data represent the 
mean ± SD of duplicate experiments. Data that are significantly different are indicated by 
asterisks as follows: *, P < 0.05 compared to vector control; **, P < 0.05 compared to 






NORE1A depletion suppresses Her2+ senescence. 
Activated Her2/Ras signaling has been shown to promote the phenotype of 
senescence (as measured by enhanced SA-β-gal activity and p21 expression) in MCF-
10A cells [62]. NORE1A is required for Ras to induce senescence [36]. Her2/Ras 
signaling to BRCA1 was also shown to promote senescence via upregulation of p21 [64], 
[111]. 
I showed in Chapter V that NORE1A acts as a communication link between Ras 
and BRCA1. I was therefore curious to determine whether inactivation of NORE1A 
would disrupt senescence signaling between Her2/Ras and BRCA1. 
To determine whether NORE1A depletion blocks the ability of Her2 to 
communicate with BRCA1 and induce senescence, I stably overexpressed a 
constitutively active Her2 mutant (V659E) in my matched set of NORE1A-/BRCA1- 
MCF-10A cells (Figure 12B). These Her2+ cells were then grown for 48 hours and 
assayed for senescence induction as measured by β-galactosidase activity and p21 
expression. 
NORE1A inactivation suppressed the ability of Her2 to induce senescence, as 
indicated by a reduction in SA-β-gal activity in Her2+/NORE1A- cells. Her2+/BRCA1- 
cells showed a ~65% increase in SA-β-gal activity compared to Her2+ control cells, and 
co-depletion of NORE1A completely suppressed the BRCA1 effect (Figure 14A). 
Her2+/NORE1A-/BRCA1- cells also showed a synergistic reduction in p21 expression 
(Figure 14B). Interestingly, NORE1A inactivation did not show a significant reduction in 
p21 expression compared to control cells. This could be explained by differences in 
NORE1A knockdown levels in our NORE1A- cells compared to NORE1A-/BRCA1- cells 
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(60% knockdown and 91% knockdown, respectively). Additionally, BRCA1 inactivation 
did not enhance expression of p21 compared to control cells. This was surprising, as 
BRCA1 knockdown has been shown to drive senescence via upregulation of both p21 
and p16 [149]. This suggests that BRCA1 inactivation is driving senescence independent 
of p53-p21 signaling in our system; possibly via upregulation of p16 or Rb. Further 
experiments are required to determine if this is the case. 
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Figure 14: NORE1A depletion suppresses senescence in Her2+/BRCA1- cells. 
(A) shBRCA1 (shB) and shNORE1A (shN) MCF-10A Her2+ cells were grown in 12-well 
plates and β-galactosidase activity was quantified after 24 hours. The percent increase 
over Her2+ control cells was measured. Data represent the mean ± SD of triplicate 
experiments. *, P < 0.05 compared to scrambled control; **, P < 0.05 compared to 
shBRCA1 (one-way ANOVA followed by Student’s t-test). (Bottom) A representative 
image of senescence induction in each set of cells. (B) Double knockdown of 
NORE1A/BRCA1 synergistically suppresses p21. (Bottom) Western blot analysis of p21 
expression from shBRCA1/shNORE1A MCF-10A Her2+ cells. The density of the bands 
was quantified using ImageJ software and relative p21 expression was quantified after 
normalizing to β-actin. (Top) Relative p21 levels expressed as a bar graph. Data represent 
the mean ± SD of three independent experiments. *, P < 0.05 compared to scrambled 









NORE1A and BRCA1 co-depletion enhances Her2/Ras transformation. 
Activation of Her2/Ras in immortalized cells promotes the phenotype of 
senescence, yet these cells can still proliferate and undergo anchorage-independent 
growth [61], classic indicators of malignant transformation. I showed earlier that co-
depletion of NORE1A and BRCA1 in MCF-10A cells had an additive effect on their 
proliferation rate. I was curious to determine if this increase in proliferation corresponded 
with an enhanced ability to grow in soft agar. Individual knockdown of NORE1A or 
BRCA1 did not permit the anchorage-independent growth of MCF-10A cells (< 7 
colonies/well). However, double knockdown of NORE1A and BRCA1 was sufficient to 
transform MCF-10A cells (> 40 colonies/well) (Figure 15). This is reminiscent of the 
transforming effect that the NORE1A-INT domain had on these cells (Figure 11C). 
Her2 overexpression alone was sufficient to promote anchorage-independent 
growth of my control MCF-10A cells (> 40 colonies/well). Furthermore, co-depletion of 
NORE1A and BRCA1 synergistically enhanced colony formation in my Her2+ cells (~6-




Figure 15: NORE1A and BRCA1 co-depletion enhances MCF-10A growth in soft 
agar. 
shBRCA1 (shB) and shNORE1A (shN) MCF-10A cells with and without Her2-
overexpression (Her2+) were plated in soft agar and grown for 2 weeks at 37C. Data 





NORE1A depletion suppresses anoikis. 
 In order for cells to become transformed they must be able to continue 
proliferating and also avoid cell death. I showed earlier in this chapter that NORE1A and 
BRCA1 loss enhances the proliferation of MCF-10A cells, and that dual inactivation of 
NORE1A and BRCA1 was sufficient to promote the growth of these cells in soft agar, a 
marker of malignant transformation. NORE1A has a well-studied role in apoptosis [34], 
[38]. Thus, I hypothesized that NORE1A loss could be conferring apoptosis resistance to 
these cells. 
Epithelial cells require contact with the surrounding extracellular matrix (ECM) in 
order to send and receive signals essential for their growth and survival [120]. Loss of 
ECM attachment can cause cells to undergo a matrix deprivation-induced apoptosis 
termed anoikis [151]. The acquisition of anoikis resistance allows cells to grow under 
anchorage-independent conditions [152], and is a crucial step in Ras-mediated breast 
tumorigenesis [52]. 
To determine whether NORE1A- MCF-10A cells were resistant to anoikis, I grew 
the NORE1A-/BRCA1- MCF-10A matched set of cells in suspension culture for 48 hours 
and assayed for total survival, or resistance to anoikis. Cell survival was enhanced by 
~200% in NORE1A knockdown cells and ~285% in NORE1A/BRCA1 double 
knockdown cells (Figure 16). Cell survival was not significantly altered by BRCA1 




Figure 16: NORE1A depletion confers anoikis resistance. 
shBRCA1 (shB) and shNORE1A (shN) MCF-10A cells were grown in suspension for 48 
hours and cell viability was determined by Trypan blue exclusion assay. Percentage of 
cell survival is represented as mean ± SD from 3 independent experiments. *, P < 0.05 







 Oncogene-induced senescence occurs as a result of cells permanently disabling 
their cell cycle machinery via activation of multiple tumor suppressor signaling 
pathways, such as the p53-p21 and p16-Rb pathways [140]. Both NORE1A and BRCA1 
play a role in Ras-induced senescence [36], [64], and can interact with p53 to promote 
p21 activation [40], [147]. Using immortalized, non-transformed MCF-10A human breast 
epithelial cells, I successfully established a viable model of constitutive Her2/Ras 
activation that allowed us to examine the effects of NORE1A and BRCA1 inactivation on 
senescence induction by these oncogenes. 
 Her2-overexpression has been reported to promote the senescent phenotype 
(enhanced SA-β-gal activity, upregulated p21 expression) in MCF-10A cells [62]. Upon 
oncogene activation, these cells have been shown to reside in a relatively stable 
intermediary state until increasing levels of stress drive them to fully senesce or 
transform [62]. For example, BRCA1 loss after Her2/Ras activation triggers a DNA 
damage response that promotes senescence [64], [111]. The fact that inactivation of a 
tumor suppressor can trigger growth arrest may seem counter-intuitive. However, this is 
actually part of a controlled suicide response initiated by cells that lose BRCA1 in order 
to avoid becoming malignant in the absence of adequate DNA repair mechanisms [148], 
and has been observed after loss of other tumor suppressors besides BRCA1, such as the 
Von Hippel-Lindau (VHL) protein [153]. Activation of Her2/Ras facilitates BRCA1 
inactivation for this purpose: as a senescence fail-safe mechanism to protect cells with 
activated Her2/Ras from malignant transformation. 
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 I discovered that NORE1A depletion disrupted the ability of Her2 expression and 
BRCA1 loss to induce senescence. This verifies the existence of a 
Her2/Ras/NORE1A/BRCA1 senescence-signaling pathway, and demonstrates that 
NORE1A inactivation is essential for cell survival after BRCA1 expression is lost. Thus, 
NORE1A loss allows the tumorigenic effects of Her2/Ras and BRCA1 dysregulation 
(e.g. accumulation of mutations caused by enhanced proliferation in the absence of error-
free DNA repair) to manifest and provides cells with the ability to subvert apoptosis and 
senescence. In effect, NORE1A appears to be monitoring the “Goldilocks” response; “too 
little” BRCA1 or “too much” Her2/Ras causes death as long as NORE1A expression is 
“just right”. Loss of NORE1A disables this response, facilitating transformation (Figure 
17). 
 Tumorigenesis is a multi-stage process comprised of the accumulation of cellular, 
genetic, and epigenetic alterations over time [154]. These alterations allow normal cells 
to progress to malignancy by overcoming pro-senescent and pro-apoptotic signaling after 
Her2/Ras activation. Since NORE1A and BRCA1 are both tumor suppressors, I 
hypothesized that their complex formation could play a role in tumor suppression. 
Consistent with Knudson’s two-hit hypothesis [155], inactivation of NORE1A or 
BRCA1 alone was not sufficient to transform immortalized MCF-10A cells into cancer 
cells in vitro, suggesting that additional oncogenic hits must be required. Interestingly, 
dual inactivation of NORE1A and BRCA1 was sufficient to transform MCF-10A cells, as 
I hypothesized would occur based on the transforming effects of the NORE1A-INT 
domain in these cells. Her2 overexpression greatly enhanced the level of transformation 
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observed in NORE1A-/BRCA1- cells. Thus, I conclude that NORE1A and BRCA1 form 
a tumor suppressor complex that can protect cells from Her2/Ras transformation. 
An important marker of malignant transformation is the ability of cells to grow 
under anchorage-independent conditions. A crucial step in obtaining anchorage-
independent growth is acquiring resistance to matrix deprivation-induced apoptosis, 
which is referred to as anoikis [152]. Non-transformed MCF-10A cells undergo anoikis 
when they lose matrix attachment, whereas Her2/Ras-transformed MCF-10A cells will 
continue to proliferate [156][157]. This Her2/Ras-induced anoikis resistance was reported 
to be due in part to activation of the Raf-ERK pathway [157], [158]. However, additional 
analysis on breast carcinoma cells suggests that neither ERK nor AKT activation are 
necessary for Ras inhibition of anoikis [52]. Thus, additional Ras signaling pathways are 
likely involved. 
I hypothesized that the pro-apoptotic Ras effector NORE1A might play a role in 
Ras-mediated anoikis resistance. I discovered that depletion of NORE1A conferred 
anoikis resistance to MCF-10A cells. Thus, in addition to facilitating senescence bypass 
after Ras activation, NORE1A inactivation also provides cells a means to subvert 
apoptotic signaling. 
 Under normal conditions, constitutive Her2/Ras signaling drives senescence by 
triggering a DNA damage response [109], [126]; or, as a fail-safe mechanism, by 
inactivating BRCA1-mediated DNA repair [64], [111]. Any Her2/Ras-positive cells that 
survive the senescent response and continue to proliferate will undergo anoikis before 
they can metastasize. If NORE1A is inactivated, neither these pro-senescent nor pro-
apoptotic pathways can be initiated in response to Her2/Ras activation. Consequently, 
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Ras-induced hyperproliferation is allowed to continue in the absence of proper DNA 
repair mechanisms, contributing to the accumulation of cancer-causing mutations. Thus, 
NORE1A inactivation facilitates Her2/Ras-driven tumor formation by allowing cells to 
continually proliferate without the barriers of apoptosis or senescence. The frequency of 
NORE1A inactivation in breast cancers (~40%) [65] could therefore offer an explanation 
for the high incidence of Ras activation (~50%) observed in sporadic breast cancers. 
 In conclusion, I propose that NORE1A is part of the surveillance machinery that 
monitors a “Goldilocks” response to Her2/Ras activation or BRCA1 inactivation: In the 
case of “too much” oncogene (Ras) or “too little” tumor suppressor (BRCA1) expression, 
NORE1A levels must be “just right” in order to prevent tumor formation (Figure 17). 
Since NORE1A and BRCA1 co-localize in response to replication stress, and loss of 
NORE1A appears to be altering the cellular response to BRCA1, it is possible that 
NORE1A plays a role in the BRCA1-mediated response to replication stress. 
Experiments examining the effect of NORE1A expression on BRCA1-mediated DNA 




Figure 17: NORE1A monitors “Goldilocks” response to Her2/Ras/BRCA1 
Earlier, I described a “Goldilocks” model for senescence whereby NORE1A monitors 
senescence induction in response to constitutive activation of Her2/Ras (i.e. “too much” 
oncogene) or inactivation of BRCA1 (i.e. “too little” tumor suppressor). NORE1A 
expression must be “just right” to monitor senescence, as loss of NORE1A expression 











BRCA1 maintains genomic stability via checkpoint activation and DNA repair. 
 Genomic instability is a hallmark of cancer development [159]. One of the main 
causes of genomic instability is the accumulation of DNA damage. This can occur in 
response to endogenous or exogenous stressors, or from errors in DNA replication [160], 
[161]. Normal cells respond to DNA damage by coordinating the activation of checkpoint 
and repair pathways [107]. If the damage persists, these cells undergo apoptosis or 
senescence. Failure to properly repair damaged DNA or activate growth inhibitory 
pathways can lead to tumor formation. 
The tumor suppressor BRCA1 acts as a central mediator of the DNA damage 
response by coordinating the formation of protein complexes involved in checkpoint 
activation and DNA repair [89]. Only a fraction of total cellular BRCA1 is in each of 
these complexes, allowing BRCA1 to form multiple interactions simultaneously [90]. 
BRCA1 and binding partners abraxas and CtIP control entry into mitosis upon DNA 
damage detection by enhancing the phosphorylation of checkpoint kinase 1 (CHK1) and 
transiently arresting the cell cycle at G2 [162]–[164], allowing the BRCA1, BRCA2, 
PALB2 and Rad51 complex to participate in homologous recombination (HR)-mediated 
DNA repair [165], [166]. BRCA1, BACH1, and TopBP1 regulate entry into S-phase, and 
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also help maintain and repair stalled replication forks during DNA replication [167], 
[168]. 
 
Genome instability is triggered by replication stress 
The majority of genomic instability that occurs in cancer cells is a result of errors 
in normal DNA replication [169]. During replication, endogenous and exogenous agents 
challenge genome integrity by pausing and destabilizing the replication fork. In most 
cases, the replisome maintains association with the stalled fork, and replication can 
resume after the stress is removed [170]. Failure to protect or restart the replication fork 
in a timely manner can cause the replisome to dissociate and the fork to collapse, leading 
to the formation of DSBs [171]. 
In response to replication fork stalling, cells trigger a replication stress response 
that promotes complex formation between BRCA1 and BACH1 helicase [172]. BACH1 
binds directly to the C-terminal BRCT repeats of BRCA1, a region that is essential for its 
tumor suppressor function [168]. This BRCA1/BACH1 complex can transiently inhibit 
DNA synthesis and participate in error-free HR-mediated DNA repair in order to resume 
progression of the stalled fork [173]. Mutations in BRCA1 or BACH1 that inhibit their 
complex formation render cells unable to participate in HR-mediated repair and are 
associated with an increased risk for breast cancer [118], [174]–[177]. 
 
Her2/Ras activation can trigger replication stress. 
Activation of oncogenes such as Her2/Ras promotes genomic instability by 
enhancing the rate of cellular proliferation [178]. This results in the depletion of 
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nucleotide pools, which subsequently impedes the progression of DNA replication forks 
[133]. Persistently stalled forks can collapse, leading to the formation of DSBs [178]. The 
replication stress and DNA damage accumulation triggered by Her2/Ras activation drives 
senescence [109], and I have shown that Her2-driven senescence requires expression of 
NORE1A. Additionally, activated Her2/Ras downregulates expression of BACH1, which 
dissociates BRCA1 from chromatin and inactivates BRCA1-mediated DNA repair [64]. 
This BRCA1 inactivation drives senescence [64], but simultaneously predisposes cells to 
mutations as they become reliant on more error-prone pathways of DNA repair [179]. 
Thus, Her2/Ras can facilitate transformation by inactivating the BRCA1/BACH1 
complex and selecting for cells that acquire secondary mutations in the absence of 
BRCA1-mediated HR repair [64], [111], [129]. 
I showed earlier that inactivation of the Ras effector NORE1A is one way that 
cells can subvert Her2/Ras-mediated growth inhibition. I observed NORE1A and BRCA1 
co-localizing in nuclear foci in response to Her2/Ras induced replication stress. I 
hypothesized that these nuclear foci were sites of replication fork stalling, and decided to 
examine the possibility that NORE1A could be participating in the BRCA1 response to 
replication stress. Currently, no role for NORE1A in DNA repair has been reported. 
Here, I show that NORE1A forms a complex with BACH1 and BRCA1. 
Furthermore, I discovered that co-inactivation of NORE1A and BRCA1 synergizes to 
suppress DNA repair. Thus, I identify a novel role for NORE1A in the control of DNA 
repair by BRCA1/BACH1. As NORE1A regulates both senescence and DNA repair, it 






NORE1A plays a role in BRCA1-mediated DNA repair. 
I observed earlier that NORE1A and BRCA1 co-localize in nuclear foci in 
response to replication stress. I also discovered that NORE1A forms a complex with 
BACH1 and BRCA1, two proteins that co-localize at stalled replication forks in order to 
maintain fork integrity and repair DNA DSBs [103], [168]. 
BRCA1 plays a key role in DNA DSB repair [89]. Consequently, BRCA1-
deficient cells are highly sensitive to drugs that induce DSBs. Doxorubicin hydrochloride 
(Dox) is an anthracycline that stabilizes the topoisomerase II complex during replication, 
causing DNA cleavage and DSB formation [180]. I subjected cells from my MCF-10A 
NORE1A-/BRCA1- matched set to Dox treatment for 24 hours and then measured their 
capacity for DNA repair using the comet assay. 
I observed a large increase in DNA damage (i.e. enhanced DNA tail moment) in 
NORE1A- and BRCA1- cells compared to control cells after treatment with Dox (Figure 
18A). Additionally, I discovered that co-depletion of NORE1A and BRCA1 synergized 
to suppress DNA repair after Dox treatment. Figure 18B shows representative control and 




Figure 18: Dual inactivation of NORE1A and BRCA1 synergizes to suppress DNA 
repair. 
(A) Matched sets of cells from my NORE1A-/BRCA1- MCF-10A system were treated 
with 0.3 µg/mL doxorubicin hydrochloride (Dox) for 24 hours to induce DNA damage. 
Cells were harvested and assayed for changes in DNA repair activity using a comet 
assay. Data was measured as comet tail moment, and represents 100 randomly chosen 
cells from two independent experiments. Results are displayed as box-and-whisker plots. 
The box includes 50% of the measured values for each condition, and the bottom and top 
of each box represent the 25th and 75th centiles, respectively. The inner line marks the 
median. Data from the upper and lower quartiles are indicated as whiskers that are 
capped at the minimum or maximum calculated values. Asterisks indicate mean values 
that are significantly different, as follows: *, P < 0.05 compared to the value for Dox 
treated control cells. **, P < 0.05 compared to the value for Dox treated shB cells. ***, P 
< 0.05 compared to the value for Dox treated shN cells. (B) Representative comet tails 







NORE1A forms a complex with BACH1 and BRCA1. 
 BACH1 is a well-studied, physiological binding partner of BRCA1 [168]. These 
two proteins form a tumor suppressor complex that plays a role in checkpoint control 
after replication stress and HR-mediated DNA repair after DNA damage [64], [103], 
[118]. I have observed NORE1A co-localizing with BRCA1 after replication stress. Since 
NORE1A can function as a nuclear scaffolding protein [36], I was curious to determine 
whether NORE1A could facilitate complex formation between BRCA1 and BACH1. 
I was able to detect an interaction between NORE1A and BACH1 when these 
proteins were overexpressed in HEK-293T cells (Figure 19A).  Furthermore, I 
determined that NORE1A expression enhances complex formation between BRCA1 and 




Figure 19: NORE1A scaffolds BRCA1 with BACH1 helicase. 
(A) HEK-293T cells were transiently transfected with either GFP-tagged NORE1A or 
Myc-tagged BACH1. Cells were lysed 24 hours after transfection and equal amounts of 
protein were immunoprecipitated for GFP. The immunoprecipitate was fractionated on an 
SDS-polyacrylamide gel and then immunoblotted with anti-GFP and anti-Myc 
antibodies. (B) HEK-293T cells were transiently transfected with either YFP-BRCA1 or 
Myc-BACH1 in the presence or absence of HA-tagged NORE1A, then lysed and 
Western blotted as above with anti-GFP, anti-HA, and anti-Myc antibodies. Fold change 







 In this chapter, I examined the possibility that NORE1A could be regulating the 
DNA repair ability of BRCA1. I proposed this hypothesis based on my observation that 
these proteins co-localize in the nucleus (at what appear to be stalled replication forks) in 
response to replication stress, and that NORE1A loss can alter the cellular response to 
BRCA1. I provide evidence to support this hypothesis by demonstrating that NORE1A 
plays a role in DNA repair. Specifically, I show that NORE1A inactivation impairs the 
ability of non-transformed human mammary epithelial cells to repair DNA DSBs, and 
that dual inactivation of NORE1A and BRCA1 synergistically suppresses the DNA repair 
ability of these cells. 
 The ability of BRCA1 to participate in homologous recombination (HR)-mediated 
DNA repair in response to DSB formation is determined by its interaction with BACH1 
helicase. Complex formation between BRCA1 and BACH1 is required for HR-mediated 
DNA repair, and depletion of either BACH1 or BRCA1 disables HR [181]. The 
BRCA1/BACH1 complex is readily detected during S-phase, specifically in response to 
replication stress caused by stalled or collapsed replication forks [104]. Interestingly, I 
was able to detect exogenous NORE1A in a complex with BACH1, and determined that 
NORE1A enhanced complex formation between BRCA1 and BACH1. Thus, it appears 
that NORE1A is scaffolding the BACH1/BRCA1 interaction. One explanation for the 
decreased DNA repair capability of the NORE1A- MCF-10A cells compared to control 
cells might therefore be impaired complex formation between BACH1/BRCA1. 
 One of the more promising therapies targeting tumor cells with BRCA1 
deficiency involves inhibition of poly-ADP ribose polymerase (PARP), a key enzyme 
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involved in SSB DNA repair. PARP inhibitors are reported to be particularly effective 
against BRCA1-null cancers, since these tumor cells are unable to use HR-mediated DSB 
repair pathways and rely solely on PARP for DNA repair [182], [183]. When PARP is 
also inhibited in these cells they cannot repair any DNA damage and are forced to 
undergo apoptosis [184]. Unfortunately, clinical trials with PARP inhibitors have been 
less than promising in treating patients with BRCA1-mutated breast cancers [185]. 
 Interestingly, it has been shown preclinically that disruption of proteins that 
interact with BRCA1 can increase PARP inhibitor sensitivity [186], [187]. Since dual 
inactivation of BRCA1 and NORE1A synergize to suppress DNA repair, it is exciting to 
speculate that NORE1A loss might render cells more susceptible to PARP inhibitor 
treatment. Preliminary experiments in our lab showed no significant differences in 
survival between my MCF-10A knockdown set of cells after treatment with the PARP 
inhibitor Olaparib (data not shown). This could be due to the concentration of drug that I 
chose or its efficacy in general. More recently, the PARP inhibitor Veliparib showed 
promise in early clinical studies when used to treat BRCA1- sporadic breast cancers in 
combination with platinum agents [188]. Thus, further experiments are required to 
determine whether NORE1A-/BRCA1- cells (and breast cancers) would be more sensitive 
to treatment with PARP inhibitors, alone or in tandem with other drugs like cisplatin. 
 In addition to its role in DNA repair, BRCA1 also has an important biological 
function as an E3 ubiquitin ligase. This sole identified enzymatic activity of BRCA1 
occurs within its N-terminal RING domain, and is largely enhanced by formation of a 
heterodimer between BRCA1 and the BRCA1-associated RING domain protein 
(BARD1) [189]. Putative targets of BRCA1-BARD1 ubiquitination include histones, γ-
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tubulin, estrogen receptor alpha (ERα), CtIP, and the checkpoint kinase 1 (CHK1) co-
activator claspin [93]–[95], [190]. While the most common function of polyubiquitin 
chains are to serve as a signal for proteolysis by the proteasome, it appears that BRCA1 
ubiquitination does not always signal degradation of its substrates [90]. In addition, this 
function of BRCA1 was shown to be disposable for its tumor suppressor function [96]. 
Thus, the biological consequences of BRCA1-mediated ubiquitination remain poorly 
understood. Recently, NORE1A was shown to scaffold the ubiquitin ligase β-TrCP in a 
Ras-regulated manner that enhances its enzymatic activity toward specific targets [83]. 
Given this information, it is interesting to speculate that NORE1A might also function as 
a Ras-regulated scaffold for BRCA1-mediated ubiquitination of its target substrates. 
Preliminary experiments in our lab have identified NORE1A as a regulator of both 
Claspin and ERα ubiquitination (unpublished data). Further experiments are required to 
determine whether this is a BRCA1-specific effect, as additional enzymes have been 





 Based on the results detailed in this dissertation, I propose that NORE1A and 
BRCA1 form a tumor suppressor complex that either participates in DNA repair or 
promotes senescence depending on the signal intensity and duration of Her2/Ras 
activation. Essentially, the NORE1A/BRCA1 complex functions to regulate the balance 
between growth arrest and repair after Her2/Ras activation (Figure 20). 
If Her2/Ras signaling persists and excessive DNA damage accumulates, cells will 
initiate a controlled suicidal response that involves the inactivation of BRCA1 [64], 
[111]. NORE1A is required for this senescence induced by Her2 (shown here) and Ras 
[36]. When NORE1A is not present in cells, they cannot undergo this “suicidal” 
senescence triggered by constitutive Her2/Ras activation or BRCA1 inactivation and will 
instead continue to grow and transform. Thus, NORE1A appears to be a key part of the 
surveillance machinery that promotes a “Goldilocks” response. Too much oncogene 
activation or too little tumor suppressor expression can cause cell death. Loss of 
NORE1A disables this effect, allowing the tumorigenic effects of Her2 and BRCA1 




Figure 20: NORE1A regulates the BRCA1 response to Ras-induced DNA damage 
In response to Ras activation, NORE1A can form a complex with BRCA1 to repair 
damaged DNA. If the damage is too great, NORE1A and BRCA1 can promote the 
activation of p21 to drive senescence. NORE1A inactivation uncouples both Her2/Ras 
and BRCA1 from senescence and impairs BRCA1-mediated DNA repair, thereby 
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